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Abstract (limit of 250 words) 
 
One of the therapeutic strategies in HIV neutralization is blocking membrane 
fusion. In this process, tight interaction between the N-terminal and C-terminal 
heptad-repeat (NHR and CHR) regions of gp41 is essential to promote membranes 
apposition and merging. We have previously developed single-chain proteins 
(named covNHR) that accurately mimic the complete gp41 NHR region in its 
trimeric conformation. They tightly bind CHR-derived peptides and show a potent 
and broad HIV inhibitory activity in vitro. However, the extremely high binding 
affinity (sub-picomolar) is not in consonance with their inhibitory activity 
(nanomolar), likely due to partial or temporal accessibility of their target in the 
virus. Here, we have designed and characterized two single-chain covNHR 
miniproteins each encompassing one of the two halves of the NHR region and 
containing two of the four sub-pockets of the NHR crevice. The two miniproteins 
fold as trimeric helical bundles as expected but while the C-terminal covNHR 
(covNHR-C) miniprotein is highly stable, the N-terminal counterpart (covNHR-N) 
shows only marginal stability that could be improved by enginnering an internal 
disulfide bond. Both miniproteins bind their respective complementary CHR 
peptides with moderate (micromolar) affinity. Moreover, the covNHR-N 
miniproteins can access their target in the context of trimeric native envelope 
proteins and show significant inhibitory activity for several HIV pseudoviruses. In 
contrast, covNHR-C cannot bind its target sequence and neither inhibits HIV, 
indicating a higher vulnerability of C-terminal part of CHR. These results may 
guide the development of novel HIV inhibitors targeting the gp41 CHR region.  
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- Design, production and characterization of mini protein HIV inhibitors 
- Engineered disulfide bond increases conformational stability 
- Protein stabilization enhances inhibitory capacity 
- NHR coiled-coil of gp41 is composed of two subdomains with different 
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Infection by the human immunodeficiency virus (HIV) is still among the worst 
global pandemics, with nearly 1 million deaths per year directly or indirectly 
associated to the infection and the rate of new infections remains high at 1.7 
million per year. However, only a few vaccine candidates have reached phase IIb or 
III clinical tests with poor or null efficacy. For these reasons, the development of an 
effective, safe and affordable treatment against HIV and new improved antivirals 
or microbicides are highly desirable against the infection. During the last decades, 
antiretroviral therapies have improved considerably the life expectancy of patients 
infected by HIV. Combined therapies with several drugs (HAART) have raised the 
genetic barrier for evolution of viral resistance and have been able to reduce the 
number of copies in the blood stream of patients to undetectable levels, keeping 
the virus latent integrated in the DNA of infected cells. Nonetheless, the emergence 
of multidrug-resistant viral strains has been observed in an increasing number of 
patients 1 and in some cases serious interactions between drugs have appeared 2. It 
is therefore necessary to expand the repertoire of potent inhibitors targeting 
different stages of the HIV replication cycle.  
Current efforts in this field have been focused on preventing the cell-virus fusion 
by blocking the HIV envelope protein (Env) 3; 4. Env is a non-covalently associated 
trimer of heterodimers of two glycoprotein subunits, gp120 and gp41 playing 
crucial roles in HIV cell infection 5; 6; 7. The gp120 sequential binding to CD4 
receptor and one of CXCR4 or CCR5 co-receptors triggers a series of large 
conformational changes in gp41 that lead to membrane fusion and insertion of the 
viral content into the cell cytoplasm 8; 9.  In this process, the gp41 subunits insert 
their N-terminal fusion peptides into the cell membrane and fold into a highly 
stable 6-helix-bundle (6HB) conformation, in which the N-terminal heptad repeat 
(NHR) regions form a central helical trimer and the three C-terminal heptad repeat 
(CHR) regions pack externally over them in an antiparallel orientation 10 ; 11. The 
energy gain from this folding process serves to bring membranes into close 
proximity and facilitiate their fusion. 
Abolishing the whole fusion stage and inhibiting the virus invasion by blocking any 
single step in the fusion process reveal to be effective strategies. Due to its key role 
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in membrane fusion, gp41 constitutes a very attractive target for the identification 
and development of fusion inhibitors. The protein NHR and CHR regions are 
temporarily exposed in a fusion intermediate state before interacting with each 
other, so some appropriate molecules able to recognize NHR or CHR regions could 
interfere with such interaction and act as fusion inhibitors 12. These are mainly 
CHR peptide mimetics 13; 14; 15; 16, artificial D-peptides 17, small compounds 18; 19 and 
also antibodies 18; 19; 20; 21. Currently, only one inhibitor from this type is approved 
for clinical use. T20, also known by its generic name as enfuvirtide, is a 36 amino 
acid polypeptide derived from the CHR and membrane proximal regions of gp41 13; 
22 . Unfortunately, its clinical use has been limited by its short half-life 23 
(proteolysis-sensitive and rapid renal filtration) requiring therefore high dosage 
injections at least twice a day. Moreover, the continuous and expensive treatment 
generates the appearance of T20-resistant viruses. Subsequently, other peptides 
and small molecule compounds directed against the coiled-coil structure of NHR 
have been developed, although very few have reached clinical stage and present 
various difficulties in their development as suitable drugs 24; 25 ; 26 ; 27. 
Even though peptides derived from the gp41 NHR region inhibit the entry of HIV 
by interacting with the CHR region, they show much less inhibitory potency due to 
their low conformational stability and higher tendency to aggregate. However, 
different strategies have succeeded stabilizing the NHR region in a trimeric helical 
conformation, with strong improvements in inhibitory potency 4; 28; 29; 30; 31; 32. 
We have previously designed small protein constructs, called covNHR, consisting 
of a single polypeptide chain with three helical regions folding together to form an 
antiparallel trimeric bundle with a similar structure to the NHR region of gp41 33; 
34. These highly stable and soluble proteins are produced recombinantly by 
expression in E. coli with good yields and do not need any posttranslational 
modifications. The covNHR proteins bind to peptides derived from the gp41 CHR 
region with very high affinity and inhibit HIV cell infection in standardized in vitro 
tests with high breadth and potency (IC50: 5-10 nM), for a wide variety of HIV 
strains 33; 34. The strong anti HIV activities of these and other NHR based constructs 
demonstrate that the CHR region of gp41 is an appealing target for therapeutic 
strategies. 
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The NHR binding surface has been described as composed of four different 
hotspots, namely an N-terminal polar pocket (NTP) 34, a shallow middle pocket 
(MP) 33, a deep and prominent hydrophobic pocket (HP), which has been widely 
used as a drug discovery target 14, and finally a C-terminal pocket (CTP) adjacent to 
the HP 35. We have reported very recently a quantitative dissection of the binding 
thermodynamics between the complementary CHR and NHR regions 36. The 
binding energy is broadly but unevenly distributed along the interface 1 and 
cooperative interactions implying at least two pockets are needed to obtain high 
affinity in the nM range 36. However, the importance of each of these binding 
pockets in the fusion inhibition remains unclear. For example, mutations in a 
covNHR variant abolishing binding at the NTP produce a 105 decrease in affinity 
for CHR peptides but only a small decrease in inhibitory potency 34. 
It is generally accepted that both CHR and NHR regions are exposed in the gp41 
prefusion intermediate and become hidden simultaneously with 6HB formation. 
However, while the formation of an NHR trimeric coiled-coil after receptor 
engagement is a prerequisite for inhibition by CHR peptide mimetics and analogs 
14, it is unclear whether all or part of the CHR region can be accessed by NHR 
mimics at an earlier stage. 
In this study, we have designed two short versions of covNHR proteins, each 
containing only two of the four pockets of the NHR crevice. A miniprotein 
corresponding to the N-terminal part of NHR (covNHR-N) harbors only NTP and 
MP, whereas a second miniprotein mimicking the C-terminal half of NHR (covNHR-
C) exposes only the HP and the CTP. The covNHR-N miniprotein proved to be quite 
unstable and was stabilized by engineering disulfide-bonds. Their biophysical and 
calorimetric characterizations have allowed us to measure the thermodynamic 
contributions to the CHR-NHR interaction in each variant. In addition, the capacity 
of these covNHR proteins to bind directly several versions of Env was assessed, 
and their capacity to inhibit different HIV-1 pseudoviruses, including T20-resistant 
strains was determined. The results improve our understanding of the role of the 
different NHR sub-sites in the inhibition targeting CHR and reveal that steric 
hindrances and conformational flexibility of gp41 are important in the 
vulnerability of the gp41 CHR region to the covNHR proteins. These results could 




Design of covNHR miniproteins 
We designed covNHR miniproteins harbouring only two of the four sub-pockets of 
the NHR crevice using the crystallographic structure of the complex between C34 
and covNHR-VQ (PDB: 6R2G) as template. This covNHR variant binds C34 with 
sub-pM affinity 34. Three different miniproteins were initially designed, one called 
covNHR-N containing the two N-terminal pockets (NTP and MP), a second one 
named as covNHR-M encompassing the two central pockets (MP and HP), and a 
third protein, designated covNHR-C, with the two C-terminal pockets (HP and 
CTP). The molecules were built by clipping the NHR helices and connecting the 
new ends with short loops. The loops were manually built establishing helix 
capping interactions and maintaining favorable backbone psi and phi angles. While 
covNHR-C was easily expressed and purified and proved to be highly stable (see 
below), the initially designed covNHR-N and covNHR-M could not be produced 
because of aggregation and lack of E. coli expression, respectively. The propensity 
of the sequences to aggregation was tested with AGGRESCAN 37. Mutations were 
added to reduce aggregation propensity and stabilize the proteins with success for 
covNHR-N. However, several versions of covNHR-M did not show any expression 
so we abandoned this design. The models were finally energy minimized and 
submitted to Molecular Dynamics simulations to test their stability (Fig. S1) and 
the final sequences are provided in Figure 1b. The molecular weights (including 
the His-tag) are 11909.47 Da for covNHR-N and 12792.82 Da for covNHR-C. 
 
Biophysical characterization of covNHR variants 
The covNHR-N and covNHR-C miniproteins (Fig. 1) were produced recombinantly 
by E. coli expression with good yields. CovNHR-N is highly soluble at physiological 
pH whereas covNHR-C shows some propensity to aggregate at concentration 
higher than 20 M. CovNHR-C is monomeric according to DLS measurements in 
both pH 2.5 and pH 7.4 buffers (50 mM glycine/HCl, pH 2.5 and 50 mM sodium 
phosphate buffer, pH 7.4), showing apparent hydrodynamic radii of 1.8-1.9 nm 
(Fig. S2a and Table S1). While covNHR-N is also monomeric at pH 7.4 (Rh=1.9 nm), 
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its hydrodynamic radius at pH 2.5 is increased up to 3.1 nm, suggesting partial 
unfolding and/or self-association (Fig. S2b and Table S1). 
The two miniproteins show Far-UV CD spectra typical of highly -helical structure 
(Fig. 2a), consistent with the designs. The -helix content of covNHR-N is 64% at 
pH 7.4, slightly lower than the expected value (72%), but appears to be partially 
unfolded at acidic pH (Fig. 2a). In contrast covNHR-C exhibits 70% of -helix at 
acid and physiological pH, close to the theoretical one (74%). 
Subsequently, the thermal stability of each protein was measured by monitoring 
the CD signal at 222 nm as a function of temperature (Fig. 2b). CovNHR-C protein 
is extremelly stable at both pH 7.4 and pH 2.5, since no unfolding transitions were 
observed even after heating up to 98°C. In contrast, covNHR-N is relatively 
unstable at pH 7.4 showing its unfolding transition at 41°C (Fig. 2b and Table S1). 
This unfolding process appears to be partially reversible upon a second 
consecutive temperature scan. CovNHR-N is progressively less stable and becomes 
more expanded upon pH decrease (Table S1). Moreover, its stability and helicity 
are slightly reduced with an increase in the buffer ionic strength (Fig. S5a).  
 
Stabilization of covNHR-N by engineering an internal disulfide bond. 
Since the unfolding temperature of covNHR-N is quite low and close to the 
physiological temperature, we seeked to further stabilize it. First, we carried out a 
limited proteolysis study of the protein using thermolysin as protease. The protein 
is quite sensitive to proteolysis at 20°C even at a low 1:10000 protein/protease 
ratio.  Most sensitive cleavage points occur around loop 1 connecting helices 1 and 
2 (Fig. S3-S4) suggesting a higher flexibility for this end of the protein. Then, using 
“Disulfide by Design” web server 38 we found two possibilities for disulfide bond 
creation connecting different structural elements of the protein by X-Cys 
mutations (Fig. 3a): Gly32 at loop 1 and either of Thr92 or Arg93, at the C-
terminus of the third helix. This region is precisely the less stable part of the 
protein according to limited proteolysis, so we decided to produce both disulfide-
bonded mutants. 
Both mutants covNHR-NSS1 (G32C/T92C) and covNHR-NSS2 (G32C/R93C) could 
be produced by E. coli expression with good yields although lower than covNHR-N. 
All purification steps were made in presence of 10 mM -mercaptoethanol and a 
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final oxidation step was carried out by extensive dialysis with buffer without 
reducing agent. Formation of the disulfide bonds was confirmed in both mutants 
using Ellman’s assay (Thermofisher).  
The structure and stability of the proteins were characterized under different 
conditions in presence and absence of 5 mM TCEP (Fig. 3b-c and Table S1). Both 
variants are monomeric in all conditions studied (Fig. S2d). They have -helical 
structure similar to covNHR-N and slightly higher in the oxidized state than in the 
reduced one. The stability of both variants at pH 7.4 in their reduced state is only 
slightly higher than that of covNHR-N, with increases in Tm of +4°C. However, in 
the oxidized state the two variants are much more stable, with additional increase 
of +20°C in Tm. The thermal stability is also strongly increased in all other 
conditions (Table S1). Moreover, the two variants are much more resistant to 
proteolysis with thermolysin at 20°C, persisting uncleaved for several hours even 
in presence of 1:500 protein-to-protease ratio (Fig. S3). These results confirm a 
very similar and strong stabilization of the proteins produced by the disulfide 
bond in both variants.  
 
Binding of the CHR peptides to covNHR variants 
To characterize the interaction between the covNHR proteins and their respective 
CHR target regions in gp41, we analyzed the binding of the Y24L peptide (gp41 
residues 638-661) to covNHR-N and its two disulfide-stabilized variants, as this 
peptide spans the N-terminal pocket (NTP) and MP (middle pocket) binding 
motifs, and the binding of N25S (gp41 residues 616-640) to covNHR-C because it 
encompasses the binding motifs of the C-terminal pocket (CTP) and the 
hydrophobic pocket (HP). 
Far-UV CD spectra of the protein-peptide mixtures were compared with those of 
the free molecules (Fig. 4a). Y24L and N25S exhibit spectra typical of unfolded 
polypeptides. An increase in negative ellipticity was observed in the 
protein:peptide mixtures indicating acquisition of helical conformation for the 
peptide as a consequence of binding onto the NHR groove. The negative ellipticity 
at 222 nm for both complexes is not significantly different suggesting similar -
helical structure in the bound states. Nevertheless, the ellipiticity increase is 
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considerably larger in the case of covNHR-N and its two stabilized variants, 
indicating a greater acquisition of helical structure in these complexes. 
Thermal denaturation experiments of mixtures between Y24L with covNHR-N or 
the disulfide-bonded variants indicate considerable stabilization of the proteins 
produced by peptide binding (Fig. S5b-d). The slopes of the transitions increase, 
indicating an increase in the enthalpy of the denaturation of the complex, as a 
consequence of the interaction, and an increase in the cooperativity of the 
unfolding process. Unfortunately, this kind of analysis could not be performed with 
covNHR-C and N25S because of the extremely high thermal stability of the protein.  
To test whether the N25S peptide binds to the HP of covNHR-C in the expected 
conformation, we recorded the near-UV CD spectra of the free and bound states 
(Fig. 4b). Upon mixing with N25S, the near-UV CD spectrum of covNHR-C exhibits 
an intense shifted negative ellipticity band centered at 293 nm produced by 
sidechains stacking of the CHR tryptophan-rich motif onto the HP, as observed in 
the postfusion structure of gp41 39 and in the complexes between C34 and covNHR 
proteins 33; 34. 
 
Thermodynamics of peptide binding  
To characterize the binding thermodynamics in detail, we performed ITC analysis 
by direct titration of the protein solutions with their corresponding peptides (Fig 5 
a-b). In our recent study, we have shown that Y24L and N25S bind to covNHR-VQ 
36 with different affinities. While the interaction between Y24L and covNHR-VQ has 
been found to be relatively tight (Kd = 90 ± 7 nM at 25°C), a higher dissociation 
constant of 3.0  0.2 M was obtained for N25S 36. 
Here, we have found that Y24L binds to covNHR-N with 1:1 stoichiometry, as 
expected, since the covNHR proteins were engineered to bind a single peptide unit 
on the crevice between the two parallel helices 33. The binding shows a 
considerable negative binding enthalpy and a significantly reduced affinity (Kd = 
0.79 ± 0.02 M at 25°C) compared that of covNHR-VQ for this peptide at the same 
temperature (Table 1) 36. The binding enthalpy is considerably more negative by 
about −25 kJ mol−1 (Fig. 5c) and there is a strong increase in binding heat capacity 
compared to the complete covNHR-VQ protein.  
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These changes in the thermodynamic magnitudes of binding may be related to a 
considerable influence of a structural stabilization of covNHR-N upon interaction 
with the Y24L peptide. This conformational stabilization upon binding was already 
suggested by the CD thermal unfolding experiments (Fig. S5b).  
To further investigate the possible structural changes induced by peptide binding 
to covNHR-N, NMR 1H-15N-HSQC spectra of the labelled protein were recorded in 
the absence and in complex with unlabelled Y24L peptide (Fig. 6). The spectrum of 
free protein (at a concentration of 800 μM) presents a poor resolution due to 
considerable line broadening and low signal dispersion. This indicates a low 
conformational stability and a certain tendency to aggregate at the high 
concentration of the NMR experiment. Drastic increases in chemical shift 
dispersion and signal resolution are observed in the HSQC spectrum in presence of 
Y24L at a saturating concentration (molar ratio 1:2), indicating strong 
conformational stabilization induced by complex formation. These data also 
corroborate perfectly the DLS experiments performed with covNHR-N at different 
concentrations and in complex with Y24L that also reveal a less expanded 
structure upon addition of Y24L (Fig. S2c). These experiments confirm a significant 
conformational instability of the covNHR-N miniprotein. 
The thermodynamic magnitudes of Y24L binding are virtually identical for the 
covNHR-NSS1 and covNHR-NSS2 mutants and quite similar to those of covNHR-N 
(Fig. 5c and Table 1), except for slightly lower binding enthalpies and significantly 
less negative heat capacities of binding. This is consistent with their higher 
conformational stability produced by the disulfide bonds, as demonstrated by the 
considerable improvement of the chemical shift dispersion observed in the free 
covNHR-NSS1 HSQC spectrum (Fig. S6). Anyhow, the conformational stabilization 
produced by the disulfide-bonds has a small impact in the binding affinity of the 
proteins for the peptide. 
The dissociation constant of the complex between N25S and covNHR-C is also 
relatively high (Kd = 1.9 ± 0.3 M at 25ºC) but in this case the value is comparable 
to that of covNHR-VQ with the same peptide (Kd = 3 ± 1 M at 25ºC). Although the 
two complexes differ in binding enthalpy by about 15 kJ.mol-1 at equal 
temperature (Fig. 5d), their binding heat capacities are identical (Table 1) 36 
suggesting a similar mode of binding of N25S to both proteins.  
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In summary, the miniproteins bind their respective complementary CHR peptides 
with moderate affinity. While the C-terminal domain encompassing the HP and the 
CTP retains a high stability and similar interactions with the CHR peptide when 
isolated from the parent molecule, the N-terminal domain, harbouring the NTP and 
MP, is intrinsically unstable and its affinity for its CHR target becomes considerably 
affected compared to covNHR-VQ. 
 
Binding to envelope proteins  
To investigate the interactions of the covNHR proteins to their respective gp41 
CHR targets in a context more akin to a native-like envelope (Env) spike, we 
carried out binding experiments with several soluble stabilized Env proteins in 
precursor and cleaved forms (Table S2). Due to the low thermal stability of 
covNHR-N, these ELISA experiments were carried out at 25°C. 
The three covNHR-N proteins showed a significant level of binding to all Envs (Fig. 
7a). The binding level is similar for the three proteins and varies depending on the 
Env variant but in all cases the binding is weaker than for the parent protein 
covNHR-VQ. These results indicate that the C-terminal part of the gp41 CHR region 
from the different Envs in both uncleaved and cleaved trimeric pre-fusion 
conformations is accessible to interaction by the covNHR proteins encompassing 
the MP and NTP. In contrast, covNHR-C did not bind to any of the tested Env 
proteins indicating that the N-terminal region of CHR is less accessible in Envs pre-
fusion conformation.  
 
HIV-1 inhibition 
Despite the fact that covNHR-C did not show any binding to Env proteins, there is a 
possibility that the CHR target could become temporarily exposed during the 
fusion process and accessible to inhibition. The inhibitory activities of the proteins 
were analyzed using the conventional TZM-bl assay and compared to that of T20. 
We have used two different HIV-1 pseudovirus strains (SF162 and MW956.26) 40 
and two pseudoviruses designed for resistance to T20 (pNL4.3 and pNL4.3 DIM) 34.  
As shown in Figure 7b and Table 2, covNHR-C did not show detectable inhibitory 
activity for any tested strain, whereas weak inhibition was obtained for covNHR-N. 
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Noteworthily, these experiments were carried out at 37°C since physiological 
temperature is necessary for fusion and infection between viruses and cells. Due to 
the low thermal stability of covNHR-N (Tm ~ 41°C), the effective concentration of 
the functional protein is most likely affected at this temperature because of protein 
unfolding, resulting in overestimated IC50 values. This may be confirmed by the 
significantly higher inhibitory activities of the two disulfide-stabilized variants. 
Nevertheless, compared to the parent protein covNHR-VQ, containing the four 
NHR binding pockets, the inhibitory activities of the covNHR-N proteins are more 
than 10 fold diminished certainly because of their much lower affinity for their 
CHR target.  
The inhibitory potency of T20 is relatively high for the SF162 and MW956.26 
strains but much lower for the pNL4-3 strains, which harbor mutations at the NTP 
pocket conferring resistance to CHR-derived peptides. In contrast, the covNHR-N 




NHR coiled-coil is composed of two subdomains of different intrinsic stability 
In this study, we have reported the subdivision of the covNHR-VQ protein into two 
well-defined miniproteins each representing about a half of the NHR coiled coil. 
Both proteins have similar molecular size, the same folding topology and are 
monomeric at physiological pH. However, covNHR-N is significantly less stable 
than covNHR-C. The complete covNHR-VQ protein already contains several 
stabilizing mutations, most of them at its N-terminal half 33, but the N-terminal 
miniprotein needed additional mutations engineering and a disulfide-bond to 
acquire significant conformational stability. In contrast, the covNHR-C miniprotein 
is highly stable without any further engineering. This indicates that the C-terminal 
half of the NHR helix trimer has a much greater intrinsic stability than the N-
terminal region.  
This is consistent with the crystal structure of a soluble, cleaved Env trimer 
construct (BG505 SOSIP.664) 41, which has reported that the N-terminal half of 
NHR is partially disordered, while the C-terminal half is structured as a helix 
trimer within the Env. However, a more recent cryo-EM structure of a native JRFL 
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Env trimer with only the C-terminal tail deleted showed the first half of the NHR 
also in helical conformation 42. The authors attributed this difference to the I559P 
mutation presents in the SOSIP construct, which destabilizes the helix. 
Nonetheless, the first half of the NHR region is rather flexible and exposed in all 
prefusion structures and does not form trimer contacts, which are essential for the 
interaction with its complementary CHR region to acquire a stable 6HB coiled-coil 
structure. We observe in fact some reminiscency of this in the structural tightening 
of covNHR-N associated with binding of the Y24L peptide, as observed in the NMR 
spectra and manifested by a considerable negative binding enthalpy being partially 
compensated by negative binding entropy. Both magnitudes and the negative 
binding heat capacity (ΔCp) are much greater than those observed for the binding 
of the same peptide to covNHR-VQ 36.  
 
Accessibility of the CHR region for interaction 
Despite their different structural stability, both miniproteins are able to interact 
with their respective CHR peptide targets with similar micromolar-range 
dissociation constants. Therefore, these miniproteins constitute very convenient 
probes to test the vulnerability of each half of the CHR region of gp41 as a binding 
target to block fusion and inhibit HIV-1. 
CovNHR-C binds its corresponding CHR peptide (N25S) with an affinity very 
similar to the parent molecule covNHR-VQ 36. Previous thermodynamic studies 
performed with the stabilized trimeric NHR construct, IQN17, and short cyclic or 
D-peptides targetting the gp41 HP have reported Kd values in the same order of 
magnitude 43; 44. The HP has been reported critical to the stabilization of 6-HB 10 
and, therefore, has represented during decades the most important target for 
identification of small-molecule HIV-1 fusion and entry inhibitors 14. In spite that 
covNHR-C contains the HP and could bind its complementary CHR peptide in 
solution, it did not interact with any of the Env molecules tested in the ELISA 
experiments, suggesting an inaccessibility of its target sequence in the context of 
the prefusion spike. 
High-resolution structures of different Env spikes in prefusion conformation have 
shown that the HP and CTP binding motifs are engaged in a tryptophan clasp 
involving the side chains of Trp623 (CTP motif), Trp628 and Trp631 (HP motif) 
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that locks the fusion peptide proximal region in its pre-fusion conformation 41; 42. 
This interaction prevents therefore accessibility of covNHR-C binding to its target. 
In contrast, the three covNHR-N proteins could bind all soluble native Envs tested, 
although the level of binding measured was lower than that of the parent covNHR-
VQ molecule containing the four NHR pockets, consistently with its lower affinity 
for the Y24L peptide. This indicates that its target region corresponding to the C-
terminal part of the α9 helix in prefusion Envs is at least partially accessible. Also, 
this region is not glycosylated downstream of N651, in contrast to the first half of 
CHR, which is much more protected by glycans. Moreover, the CHR region near the 
MPER has been described as highly flexible 45; 46; 47. This suggests that covNHR-N 
proteins may be able to interact with the CHR region without the need of CD4 and 
co-receptor attachment. A similar observation has been made for 5-Helix 48; 49.  
 
Miniproteins as potencial HIV-1 inhibitors 
The covNHR-C protein was unable to inhibit any of the HIV-1 strains used in the 
assays, despite its high stability and the moderate affinity for its target CHR 
sequence, even though its target region may become transiently accessible during 
the fusion process. It is possible that micromolar affinity for its target is not 
sufficient to compensate for this transient exposure. 
However, we have found that covNHR-N and its disulfide-stabilized mutants have 
similar affinities for Y24L as covNHR-C for N25S, and yet they show significant 
inhibitory activities. Remarkably, the two stable disulfide-bonded mutants reach 
IC50 values of 30-40 nM for T20-resistant strains and moderate sub-micromolar 
IC50 values for the other pseudoviruses, well below the measured dissociation 
constants for the Y24L peptide (low micromolar). This is in contrast with other 
CHR-targetting inhibitors such as 5-helix and our covNHR-VQ molecule, which 
show sub-picomolar Kd for CHR peptides but only low-nanomolar IC50 values for 
virus inhibition. 
The lack of correlation between target binding affinity and inhibitory potency in a 
series of 5-helix and CHR-peptide mutants has been explained by Root and 
coworkers according to a kinetic dependency of fusion inhibition 50; 51. According 
to their model, inhibitor binding to gp41 would only occur after CD4 activation in 
the fusion intermediate state, which transiently exposes the target epitope. For 
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tightly binding inhibitors, IC50 is limited to a minimum of kf/kon, i.e., the ratio 
between rates of target epitope occlusion and inhibitor association. On the other 
hand, for low affinity inhibitors, with much higher dissociation rates (koff), binding 
equilibrium would be established during the window of target epitope exposure 
and then IC50 is correlated to the equilibrium dissociation constant KD. This results 
in IC50 ≥ KD, as observed for 5-helix variants, covNHR-VQ and different CHR-
derived peptides. However, for the covNHR-SS1 and covNHR-SS2 proteins, IC50 is 
much lower than KD (about 5 μM at 37°C, extrapolated from parameters of Table 
1). 
A possibility that explains the relatively high inhibitory efficiency of our 
miniproteins is that CHR accessibility in the fusion intermediate may be 
considerably higher than for larger molecules, such as 5-helix or covNHR-VQ in the 
context of the virus. This would give them a fundamental advantage as fusion 
inhibitors, since less restricted access to their target would provide a broader 
margin for affinity optimization to improve their inhibitory activity. 
A second possibility is that the covNHR-N miniproteins could be able to block 
fusion at an earlier stage than the CD4-activated fusion intermediate. We have 
shown here that covNHR-N proteins containing the NTP and MP can bind native 
Envs, whereas covNHR-C protein cannot and this binding ability correlates with 
inhibitory activity. Binding to the flexible second half of CHR may perturb the four-
helix collar of gp41 that grasps gp120 N- and C-termini, thus producing 
destabilization of the spike. It has been reported that MPER-targeting neutralizing 
antibodies, as well as antibodies targeting a conformational epitope mainly 
composed by HR2 (CHR) regions from two gp41 protomers, act by destabilizing 
the Env trimer and producing shedding 52; 53. The possibility that this mechanism 
also applies to the covNHR-N miniproteins deserves further investigation. 
Therefore, there is considerable margin for improvement of the covNHR-N 
miniproteins by engineering new modifications increasing their stability, as well as 
by improving the modest binding affinity for their target adding, for instance, new 
motifs targeting the nearby MPER region.  
 
In conclusion, we have designed, produced and characterized two single chain 
covNHR miniproteins each mimicking one of the halves of the gp41 NHR region. 
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These miniproteins fold autonomously and represent subdomains of NHR, with 
very different intrinsic stability. Although both covNHR proteins can bind their 
respective complementary CHR peptides with similar affinity, the C-terminal 
protein cannot bind its target in soluble prefusion Env spikes and does not show 
any HIV-1 inhibitory activity in vitro. In contrast, the N-terminal proteins show 
significant capacity to bind the Env spikes and are capable to inhibit HIV-1 with a 
relatively high potency, suggesting that their small size confers them a particular 
advantage to access their target in the virion context. These results show a special 
vulnerability of the flexible C-terminal end of the gp41 CHR region to novel fusion 
inhibitors.  
 
Materials and Methods. 
 
Protein and peptide samples 
The NHR and CHR gp41 sequences used in this work are described in Figure 1. The 
reference gp41 sequence was taken from the full gp160 precursor glycoprotein of 
the HIV-1 BRU isolate (Swiss-Prot entry sp|P03377|ENV_HV1BR). The covNHR 
miniproteins were computationally designed using SwissPDBviewer 54 and 
YASARA software 55. The DNA encoding the protein sequences were synthesized 
and cloned into pET303 expresion vectors (Thermofisher Scientific, Waltham, USA). 
To facilitate purification by Ni-Sepharose affinity chromatography, the protein 
sequences were histidine tagged at the C-terminus with the sequence 
GGGGSHHHHHH. The covNHR proteins were produced and purified following the 
protocol previously described 33. Synthetic CHR peptides, both N-acetylated and C-
amidated, were acquired from Genecust (Luxembourg), with a purity > 95%. 
Protein and peptide concentrations were determined by UV absorption 
measurements at 280 nm using the extinction coefficients calculated according to 




CD spectra were recorded in a Jasco J-715 spectropolarimeter (Jasco, Tokyo, 
Japan) equipped with Peltier-thermostatic cell holder. Measurements of the far-UV 
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CD spectra (260–200 nm) were made with a 1 mm path length quartz cuvette at a 
protein concentration of ~20 M. Spectra were recorded at a scan rate of 100 
nm/min, 1 nm step resolution, 1 s response, and 1 nm bandwidth. The resulting 
spectra were usually the average of five scans and the percentage of -helical 
structure was estimated from the far-UV CD spectra as described elsewhere 57. In 
thermal melting experiments, the CD signal was monitored as a function of 
temperature at 222 nm.  
Near-UV CD spectra (350–250 nm) were measured at a protein concentration of 
~15 M using a 5 mm cuvette and were typically the average of 20 scans. Each 
spectrum was corrected by baseline subtraction using the blank spectrum 
obtained with the buffer and finally the CD signal was normalized to molar 
ellipticity ([], in deg·dmol–1·cm2). The interaction experiments with CHR peptides 
were carried at a 1:2 molar ratio between the proteins and the corresponding 
peptide. 
 
Dynamic light scattering 
The particle sizes of the covNHR proteins were assessed by DLS measurements 
using a DynaPro MS-X instrument (Wyatt, Santa Barbara, CA). Dynamics software 
(Wyatt Technology Corporation, Santa Barbara, CA, USA) was used in data 
collection and processing. Sets of DLS data were measured at 25°C with an average 
number of 50 acquisitions and an acquisition time of 10 seconds.  
 
Limited proteolysis 
Proteolysis experiments were carried out using thermolysin as protease (Sigma, St 
Louis, MO) in 50 mM HEPES, 100 mM NaCl, 5 mM CaCl2 pH 7.2. Aliquots of the 
covNHR proteins at 30 µM concentration, previously dialyzed in the buffer and 
equilibrated at the desired temperature, were mixed with thermolysin at different 
protein:protease ratios and incubated in a thermoblock at 20ºC. The reaction was 
stopped at different times by adding EDTA to reach 20 mM concentration and the 
sample aliquots were immediately frozen. The samples were analyzed by SDS-
PAGE in Tris/Tricine buffers and by HPLC coupled to ESI-MS in a WATERS LCT 
Premier XE instrument equipped with a time-of-flight analyzer. Fragments were 
identified using the ExPasy Findpept tool (https://web.expasy.org/findpept/). 
 19 
 
Isothermal titration calorimetry 
ITC measurements were carried out in a Microcal VP-ITC calorimeter (Malvern 
Instruments, Worcestershire, UK). The protein solutions were titrated with 25 
injections of 5 L of the peptide solution at 480 sec intervals. Protein 
concentration in the cell was around 20 μM, while the ligands in the syringe were 
typically at 200-300 μM. The experiments were carried out in 50 mM sodium 
phosphate buffer, pH 7.4. As a blank, an independent experiment with only buffer 
in the calorimeter’s cell was performed with the same peptide solution to 
determine the corresponding heats of dilution. The experimental thermograms 
were baseline corrected and the peaks were integrated to determine the heats 
produced by each ligand injection. Finally, each heat was normalized per mole of 
added ligand. The resulting binding isotherms were fitted using a binding model of 
identical and independent sites, allowing the determination of the binding 
constant, Kb, the binding enthalpy, ΔHb, and the binding stoichiometry, n, for each 
interaction. From these values, the Gibbs energy and entropy of binding could be 
derived as ΔGb = −RT·ln Kb and T·ΔSb = ΔHb − ΔGb. Binding heat capacities were 
determined from the slope of the dependences of the binding enthalpies measured 
at different temperatures. 
 
NMR spectroscopy  
NMR experiments were performed on a Varian Direct Drive 600 MHz spectrometer 
(Varian, California, USA). The protein samples were labelled with 15N following a 
protocol established elsewhere 58. The protein was dissolved at 0.8 mM in 50 mM 
sodium phosphate pH 7.4, containing 10% D2O. To prepare a protein-peptide 
mixture, the lyophilized peptide was dissolved in H20 at a concentration of 1.6 mM 
and the pH was adjusted to pH 7.4. Then this peptide solution was further 
lyophilized. Subsequently, the newly lyophilized peptide was dissolved with the 
protein solution to reach a final concentration of 1.6 mM.  1H-15N 2D-HSQC spectra 





Binding to HIV-1 envelope spikes 
The capacity of the covNHR proteins to bind soluble HIV-1 envelope proteins (Env) 
was determined by ELISA. Briefly, 96-well ELISA plates (Maxisorp, Nunc) were 
coated at 4 °C overnight with various Envs (Table S2) in 0.1 M bicarbonate buffer 
(pH 9.6). After saturation with 2% BSA, 0.05% Tween in PBS for 1.5 h at 25°C, 0.01 
µM of covNHR molecules (100 µL diluted in 1% BSA 0.05% Tween solution) were 
added and incubated for 2 h at room temperature. The plate was then washed five 
times and covNHR binding was detected with 100µL anti-6X Histag antibody 
conjugated to horseradish peroxidase (HRP) (Abcam) at 1/10000 dilution 
incubated for 1 hour at room temperature. Antibody binding was then revealed 
with tetramethylbenzidine (TMB) substrate buffer, the reaction was stopped with 
1M H2SO4 and optical density was read at 450 nm with a Molecular Device Plate 
Reader equipped with SoftMax Pro 6 program. Backgound binding was measured 
in plates without Env and subtracted from the data. The percentage of binding was 
calculated using the readings with wells coated with His-tagged Env incubated 
with PBS buffer instead of covNHR molecules as control 100% binding.  
 
HIV-1 inhibitory assays 
The inhibition of HIV replication was determined using the conventional TZM-bl 
assay measured as a function of reductions in Tat-regulated Firefly luciferase (Luc) 
reporter gene expression 60. Pseudoviruses expressing different Env were tested 
for HIV inhibitory potential 40. The IC50, the concentration (in nM) of inhibitor 
inducing a 50% decrease in relative luminometer units (RLU), corresponding to a 
50% decrease in virus replication was calculated by non-linear regression using a 
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Figure 1. Design of covNHR miniproteins. (a) Crystallographic structure of 
covNHR-VQ in complex with C34 (pdb: 6R2G). CovNHR-VQ is represented in 
golden color and the C34 peptide in blue and red. The subdomains corresponding 
to covNHR-N and covNHR-C are respectively underlined by the green and magenta 
dashed boxes. Models of covNHR-C (magenta) and covNHR-N (green) are shown. 
(b) Sequence alignment of the covNHR proteins. Residues in bold indicate 
mutations engineered in the original design of covNHR-VQ. Mutations in red were 
engineered in this work. (c) Sequences of the CHR peptides used for binding 
experiments in this study. Residues corresponding to the different binding pocket 
motifs are colored as follows: CTP in orange, HP in cyan, MP in blue and NTP in 
red. 
 
Figure 2. Secondary structure and thermal stability of covNHR-N and covNHR-C. 
(a) Far UV CD spectra of covNHR-N (black lines) and covNHR-C (grey lines) at pH 
2.5 (dashed lines) and pH 7.4 (solid lines). (b) Thermal unfolding of covNHR-N 
(black line) and covNHR-C (grey line) followed by monitoring the CD signal at 222 
nm.  
 
Figure 3. Engineering a disulfide bond into covNHR-N protein. (a) Model of 
covNHR-NSS1 (G32C/T92C) showing the location of the residues choosen for 
mutations. (b) Far UV CD spectra of covNHR-NSS1 (black lines) and covNHR-SS2 
(grey lines) in the presence (dashed lines) and absence (solid lines) of 5 mM TCEP. 
(c) Comparison of the thermal unfolding of reduced (black circle symbols) and 
oxidized (black square symbols) covNHR-NSS2 with covNHR-N (grey symbols) 
followed by monitoring the CD signal at 222 nm. Symbols represent the 
experimental data and the solid lines correspond to the best fitting carried out 
using a two states unfolding model.  
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Figure 4. Interaction between covNHR proteins with the corresponding peptides 
monitored by far-UV and near-UV CD. (a) Far UV CD spectra of free covNHR 
proteins and 1:2 mixtures of the proteins with the corresponding CHR peptide. 
Spectra are normalized per mole and represented as follow: 1:2 mixtures (solid 
lines); free covNHR variants (dotted lines); free peptide (dashed lines); sum of the 
spectra of the free molecules (dashed-dotted lines). Protein concentrations used 
were 20 µM. (b) Near UV CD spectra of isolated covNHR-C and in complex with 
N25S at a ratio 1:2. 
 
Figure 5. Isothermal titration calorimetry experiments of CHR binding. 
Thermograms and ITC binding isotherms of Y24L binding to covNHR-N (a) and of 
N25S binding to covNHR-C (b) at 20°C. The symbols correspond to the 
experimental heats and the lines represent the fittings using a binding model of n 
identical and independent sites. (c-d). Comparison of the thermodynamic binding 
parameters of Y24L (c) and N25S (d) to the covNHR proteins at 25°C. The values 
have been calculated from the parameters taken from Table 1. 
 
Figure 6. 1H-15N HSQC spectra of covNHR-N free (a) and bound with an excess of 
Y24L at a ratio 1:2 (b). 
 
Figure 7. (a) Binding of covNHR proteins to different soluble Envs measured by 
ELISA. CovNHR binding to Env was detected using anti-Histag Ab as primary 
antibody. Background binding was measured without Env and subtracted from the 
data. 100% positive control was measured with wells directly coated with a His-
tagged Env. Data correspond to mean ± S.D. values of three independent 
measurements. (b) HIV-1 inhibitory activity of covNHR miniproteins and T20 on a 
T20 resistant variant. In vitro inhibition of pNL4-3 DIM pseudovirus infection of 
TZM-bL cells by fusion inhibitors added at different concentrations. Data are the 
mean ± S.D. of three independent measurements. Regression curves were plotted. 
using a non-linear regression using a sigmoidal Hill function, as implemented in 
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Table 1. Thermodynamic parameters of binding of gp41 CHR peptides to covNHR 
proteins measured by ITC. 
	  








Y24L 25 0.090 ± 0.007 -63 ± 1 0.83 -1.6 ± 0.1 
N25S 25 3 ± 1 -34 ± 2 1 -1.5 ± 0.2 
covNHR-N Y24L 
10 0.23 ± 0.02 -46 ± 0.4 0.86 
-2.8 ± 0.2 
15 0.29 ± 0.02 -61 ± 0.6 0.84 
20 0.44 ± 0.02 -76 ± 1.4 0.8 
25 0.79 ± 0.02 -88 ± 0.5 0.91 
covNHR-
NSS1 Y24L 
10 0.27 ± 0.02 -47.6 ± 0.5 1.04 
-2.0 ± 0.4 
15 0.37 ± 0.02 -57.2 ± 0.4 0.83 
20 0.5 ± 0.7 -66.0 ± 1.2 1.04 
25 1.1 ± 0.2 -79.6 ± 2.1 1.1 
covNHR-
NSS2 Y24L 
10 0.21 ± 0.01 -48.3 ± 0.3 0.99 
-2.1 ± 0.3 
15 0.29 ± 0.02 -59.5 ± 0.5 0.94 
20 0.51 ± 0.02 -69.5 ± 0.4 1.16 
25 1.1 ± 0.3 -85 ± 4 1.0 
covNHR-C N25S 
10 0.24 ± 0.4 -28 ± 0.8 0.84 
-1.5 ± 0.2 
15 0.31 ± 0.06  -32 ± 1 0.8 
20 0.48 ± 0.09 -42 ± 1.4 1.03 
25 1.9 ± 0.3 -49 ± 2.6 0.94 
Errors correspond to 95% confidence intervals of the fittings. 
a. Data taken from Jurado et al., 2020 36. 
	  
Table 1
Table 2. In vitro HIV-1 inhibition by covNHR proteins and T20. Inhibitory activity 
(IC50 nM ± S.D. of triplicates) was measured with the standard TZM-bl assay using 










pNL4-3 XCS 740 ± 100 37 ± 6  39 ± 4 - 2.0 ± 0.3 182 ± 25 
pNL4-3 (DIM)a 284 ± 15 32 ± 7 37 ± 3 - 3.1 ± 0.3 490 ± 260 
SF162 - 162 ± 14 126 ± 26 - 8 ± 2 51 ± 1 
MW965.26 740 ± 260 188 ± 36 220 ± 9 - 2 ± 1 4 ± 1 
a. T20-resistant strain 
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